June 24, 2015
Below are current clinical trials.1 studies in Essential thrombocythemia
(open studies only).
Filter this list of studies by location, status and more.
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Study type: Interventional What is this?
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase: II What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study
The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells (bone marrow transplantation) will be successful in people who have advanced primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring. This study plans to evaluate whether adding the drug Ruxolitinib will further aid in reducing pre-transplant spleen size, improve physical performance levels and reduce adverse events (side effects) related to the transplant. Ruxolitinib is a drug that is approved by the FDA for the treatment of patients with advanced forms of myelofibrosis. Using Ruxolitinib prior to stem cell transplantation is experimental.
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
Print study details
- Scottsdale/Phoenix, Arizona: 13-003340
NCT ID: NCT01790295
Sponsor Protocol Number: MPD-RC 114
- Thrombocythemia. Merck Manuals Professional Version. http://www.merckmanuals.com/professional/SearchResults?query=essential+thrombocythemia. Accessed May 11, 2015.
- Tefferi A. Diagnosis and clinical manifestations of essential thrombocythemia. http://www.uptodate.com/home. Accessed May 11, 2015.
- What are thrombocythemia and thrombocytosis? National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/thrm. Accessed May 11, 2015.
- Essential thrombocythemia. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/myeloproliferative/HealthProfessional/page5. Accessed May 11, 2015.
- Tefferi A. Prognosis and treatment of essential thrombocythemia. http://www.uptodate.com/home. Accessed May 11, 2015.
- Myeloproliferative disorders. Lab Tests Online. http://labtestsonline.org/understanding/conditions/myelopro-disorders/start/2. Accessed May 11, 2015.
- Mesa RA (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. May 16, 2015.
- Stroke: Hope through research. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/stroke/stroke.htm. Accessed May 19, 2015.
- Warning signs of a heart attack. http://www.heart.org/HEARTORG/Conditions/HeartAttack/WarningSignsofaHeartAttack/Warning-Signs-of-a-Heart-Attack_UCM_002039_Article.jsp. Accessed May 12, 2015.
- Chronic myeloproliferative neoplasms treatment. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/myeloproliferative/Patient/page1/AllPages. Accessed May 13, 2015.